Breaking News
8 hours ago
Vaibhavi M.
FDA approves EPKINLY + R2 for relapsed or refractory follicular lymphoma, offering stronger responses and a new chemotherapy-free treatment option.
Vaibhavi M.
Thermo Fisher opens its Philadelphia ATxCC, expanding support for cell and gene therapy development with advanced labs and collaboration resources.
Vaibhavi M.
Roche’s Phase III lidERA trial shows giredestrant significantly improves invasive disease-free survival in early-stage ER+, HER2– breast cancer.
Vaibhavi M.
Merck reports positive Phase 2 CADENCE results for WINREVAIR in CpcPH due to HFpEF, showing significant reduction in pulmonary vascular resistance.
Vaibhavi M.